GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Debt-to-EBITDA

OABI (OmniAb) Debt-to-EBITDA : -0.40 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OmniAb Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

OmniAb's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.75 Mil. OmniAb's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $20.09 Mil. OmniAb's annualized EBITDA for the quarter that ended in Sep. 2024 was $-59.35 Mil. OmniAb's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for OmniAb's Debt-to-EBITDA or its related term are showing as below:

OABI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.07   Med: -0.64   Max: -0.25
Current: -0.41

During the past 5 years, the highest Debt-to-EBITDA Ratio of OmniAb was -0.25. The lowest was -3.07. And the median was -0.64.

OABI's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs OABI: -0.41

OmniAb Debt-to-EBITDA Historical Data

The historical data trend for OmniAb's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Debt-to-EBITDA Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- -0.25 -0.77 -3.07 -0.51

OmniAb Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.39 -0.35 -0.60 -0.40

Competitive Comparison of OmniAb's Debt-to-EBITDA

For the Biotechnology subindustry, OmniAb's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OmniAb's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OmniAb's Debt-to-EBITDA falls into.



OmniAb Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

OmniAb's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.486 + 22.075) / -49.922
=-0.51

OmniAb's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.751 + 20.088) / -59.348
=-0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


OmniAb  (NAS:OABI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


OmniAb Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OmniAb's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


OmniAb Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Executives
Matthew W Foehr director, officer: President & CEO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Kurt A Gustafson officer: EVP, Finance and CFO 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Charles S Berkman officer: See Remarks 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Steven Love director C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean director, 10 percent owner 65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866